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ABSTRACT
RNA interference (RNAi) is a simple and powerful tool
widely used for studying gene function in a number of
species. Recently, inducible regulation of RNAi in
mammalian cells using either tetracycline- or ecdy-
sone-responsive systems has been developed to pre-
vent potential lethalityor non-physiological responses
associated with persistent suppression of genes that
are essential for cell survival or cell cycle progression.
Hereweshowthat the inducibleregulationofRNAialso
can be achieved by using a Cre–LoxP approach. We
demonstrate that the insertion of a loxP-flanked neo-
mycin cassette into RNA polymerase III promoter,
which controls a vector-based RNAi unit, impairs the
promoter activity. However, the expression of RNAi
construct can be completely restored upon the
removal of the neo cassette using a tamoxifen induci-
ble Cre construct.Weshow that thissystemworks with
high efficiency in suppression of two endogenous
genes, Fgfr2 and Survivin, in mouse embryonic stem
(ES) cells, as evidenced by the decrease of levels of
gene expression, reduced cell proliferation and colony
formation. This system provides a potentially impor-
tant yet simple approach to establish mutant mouse
strains for functional study at defined stages upon
turning on the inducible switches controlled by the
Cre–LoxP system.
INTRODUCTION
Recent advances in RNAi have made it possible to degrade
specific mRNAs of any endogenous genes in mammals (1–3).
The most common procedure consists of the introduction of a
21 nt double-stranded RNA (dsRNA) into the cells using a
specific transfectant. The sequence of this dsRNA or small
hairpin RNA (shRNA) has to be perfectly homologous and
unique to a region of the targeted mRNA. After 1–3 days,
expression of the target gene is dramatically reduced and
this allows investigations on the function of the gene.
Although powerful on the cell culture level, this procedure
is limited by the short period of action of the dsRNA. This
limitation leads to the development of plasmid- and viral-
based vectors, which can be stably integrated into host genome
and produce shRNAs to suppress target genes (4–9).
Logically, several recent studies developed inducible reg-
ulation of RNAi in mammalian cells using either tetracycline-
or ecdysone-responsive systems (10,11). These approaches
prevent potential lethality or non-physiological responses
associated with persistent suppression of genes that are essen-
tial for cell survival or cell cycle progression. As the initial
applications, a number of endogenous genes, including DNA
methyltransferase 1, p53 and p21, have been successfully
knocked down in cultured cells (10,12).
Another inducible system is Cre-LoxP system, which has
been most widely used in gene targeting field (13,14). Numer-
ous transgenic mouse strains expressing Cre at specific tissues/
organs have been developed to achieve spatial and temporal
control of gene expression (15). Apparently, if the RNAi vec-
tors can be modified to allow inducibility by the Cre–LoxP
system, it will eventually allow the utilization of the large
collection of Cre transgenic mice and significantly enhance
our ability to use RNAi system to decipher gene function
in vivo. Here, we demonstrate that the combination of
RNAi and Cre–LoxP can be used in ES cells for inducible
suppression of both an exogenous gene, GFP, and endogenous
genes, Fgfr2 and Survivin.
MATERIALS AND METHODS
Vector design and engineering
The original mouse U6 promoter (8) was remodeled to allow
insertion of the neomycine cassette. First, we removed the SalI
site of the polylinker, deleted 45 bp from128 to83 of the U6
promoter and replaced it with a SalI site by site-directed
mutagenesis (Stratagene, La Jolla, CA). After restriction by
SalI, a 1938 bp XhoI and SalI fragment containing the ploxPneo
(16) was inserted. We then mutated the ApaI site of the neomy-
cine cassette using the previous Stratagene kit (the insertion
of the first oligonucleotide in the polylinker required one
ApaI-restriction step). This final version of the construct can
be used to perform ligation of both oligonucleotides as
previously described (8) for eGFP and subsequent RNAi
experiments. For FGFR2, the oligonucleotides used are 1A,
*To whom correspondence should be addressed. Tel: +1 301 402 7225; Fax: +1 301 480 1135; Email: chuxiad@bdg10.niddk.nih.gov
Nucleic Acids Research, Vol. 32 No. 10 ª Oxford University Press 2004; all rights reserved
Nucleic Acids Research, 2004, Vol. 32, No. 10 e85
DOI: 10.1093/nar/gnh083
 Published online June 15, 2004
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/32/10/e85/1053647 by Inserm
/D
isc user on 04 July 2019
50-GGCCTCAGCGTTCCTGAGCGA-30; 1B, 50-AGCTTCG-
CTCAGGAACGCTGAGGCC-30; 2A, 50-AGCTTCGCTCA-
GGAACGCTGAGGCCCTTTTTG-30; 2B, 50-AATTCAAA-
AAGGGCCTCAGCGTTCCTGAGCGA-30. For Survivin,
the oligonucleotides used are 1A, 50-GGCCTCCTAGCAG-
GATCTTAA-30; 1B, 50-AGCTTTAAGATCCTGCTAGGAG-
GCC- 30; 2A, 50-AGCTTTAAGATCCTGCTAGGAGGCCC-
TTTTTG-30; 2B, 50-AATTCAAAAAGGGCCTCCTAGCAG-
GATCTTAA-30.
Cell culture and treatment
eGFP-expressing transformed mammary tumor cells have
been produced following transfection of W069 cells (17)
with pCMS-eGFP (Clonetech, Palo Alto, CA) using lipofec-
tamine 2000 following instructions of the manufacturer (Invi-
trogen, Carlsbad, CA). The eGFP-expressing cells were sorted
twice at 7 and 30 days after transfection using an FACS Cali-
bur (Becton-Dickson, San Jose, CA). Transient and stable
transfections were performed on BOSC23 and W069 cells
with lipofectamine 2000. Briefly, cells are seeded 1 day
prior to transfection at 80% confluence in six-well plates
and transfected with 100 ng of pCMS-eGFP and 3 mg of
the different pBS vectors. For stable transfections and selec-
tion of Cre-ERT2 clones, we used a ratio of 1/10 for Cre-ERT2
expressing vector on hygromycine resistance vector. ES cells
are transfected by electroporation with 20 mg of vector for two
10 cm plates. Selections with hygromycine (200 mg/ml) and/or
G418 (300 mg/ml) are performed 36 h following transfections.
Resistant colonies were picked to a 96-well plate after 8 days
of selection and several clones were analyzed (PCR on geno-
mic DNA, RT–PCR on total RNA). Treatments with 4HT
(Sigma, St Louis, MO) (1 mM) were performed one day
after transfection. Growth curves are obtained by counting
replicated six-wells of ES cells. Treatment by 4HT or vehicle
(ethanol) was started one day after plating. Cells were counted
every 24 h for monitoring proliferation. For colony formation
assay, ES cells were plated into a six-well plate at a density of
300 cells/well and treatment by 4HT or vehicle (ethanol) was
started 24 h later. Counting was performed on six different
wells for each condition 6 days after plating. Staining was
performed using Accustain (Giemsa Stain, modified from
Sigma) following instructions provided by the manufacturer.
Fluorescence experiments
Fluorescent levels of eGFP-transfected cells have been mon-
itored every day and images have been analyzed and captured
using a green fluorescent microscope (Olympus IX81, IX2-
UCB) and the IPLab software 3.6.3 on a Power Macintosh G4.
RNA preparation and reverse transcription (RT)
experiments
Total RNAs are prepared using the Rneasy Mini kit from
Qiagen, 0.5–1 mg of RNA are used to perform RT using
the kit provided by Roche Applied Science (Indianapolis,
IN) following the manufacturer instructions.
PCR experiments
PCR experiments are performed on a Perkin-Elmer 9700
machine using 2.5 U of Taq polymerase from GeneChoice,
2.5 mM MgCl2, 0.2 mM dNTP mix, 100 ng of each
oligonucleotide. During these experiments, 1 mL of cDNA
or 100 ng of genomic DNA are used.
Primers for Fgfr2 (RT) (Tm = 60C): 50-AAGGTTTACA-
GCGATGCCCA-30; 50-ACCACCATGCAGGCGATTAA-30.
Primers for Neo (Tm = 68C): 50-CGCACAGACTTGTGG-
GAGAA-30; 50-GCTGCTAAAGCGCATGCTCC-30.
Primers for Recomb (Tm = 60C): 50-CGCACA-
GACTTGTGGGAGAA-30; 50-CACAATTACTTTACAGT-
TAG- 30.
RESULTS
To develop an inducible approach for RNAi, we modified the
polymerase III U6 promoter (18) to make a ‘spatio–temporal’
switch that is suitable for the Cre–LoxP system (19–21). The
U6 promoter contains three major regulatory elements, which
include a TATA box between 31 and 26, a proximal
sequence element (PSE) between 68 and 49 and a distal
sequence element (DSE) between247 and225 (Figure 1A).
It has been shown that all three elements are required for the
Figure 1. Vectors using for interference study. (A) Structure of the mouse U6
(mU6) promoter and of its three major regulatory elements (TATA box, TATA;
Proximal Site Enhancer, PSE; Distal Site Enhancer, DSE). +1 corresponds to
the transcription start site (polylinker in the empty vector). (B) The pBS/U6-
Neo vector carried a ploxPneo cassette inserted between the PSE and the DSE
inside the mU6 promoter. Expression of the neomycine cassette in the cells
enables selection of positive stable clones with G418. (C) The pBS/U6–LoxP is
the result of the recombination event by one Cre recombinase enzyme on the
pBS/U6-Neo. (D–F) Same constructs as shown in (A–C), respectively, but with
two double oligonucleotides specifically against eGFP inserted for shRNA.
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cooperative binding of proteins, and the DSE is critical for the
stability of the DNA–protein complex and the activation of
both proximal elements (18). We assumed that the distances
between these three elements are critical while the actual
sequences of nucleotides are not. We therefore deleted 45 bp
of sequences between the DSE and PSE, and replaced
them with a neomycin cassette flanked by two LoxP sites
(ploxPneo) (16) (Figure 1B). The insertion of the ploxPneo
(total length: 1938 bp) dramatically increases distance
between DSE and PSE and is predicted to severely disrupt
the U6 promoter activity. After deleting the ploxPneo with
Cre, the critical distance is restored due to the retention of a
loxP and the flanking restriction sites (Figure 1C). We pre-
dicted that the promoter activity should be restored. If these
predictions are correct, the combination of the Cre–loxP sys-
tem and the RNAi technology could be used to regulate gene
expression both in vitro and in vivo.
To provide a quick assay on the efficiency of our plasmids,
we first targeted the eGFP mRNA in transient transfections.
Oligonucleotides against eGFP were introduced in the above
three constructs to generate the pBS/U6-eGFP (Figure 1D),
pBS/U6-Neo-eGFP (Figure 1E) and pBS/U6-LoxP-eGFP
(Figure 1F) constructs. BOSC23 cells were used in the
assay because of their high transfection efficiency. We showed
that co-transfection of an eGFP-expressing vector (pCMS-
eGFP) with pBS/U6 (shown in Figure 1A) produced high
levels of eGFP expression (Figure 2A). The expression of
eGFP was repressed by co-transfection of the pBS/U6-
eGFP (shown in Figure 1D) (Figure 2B), indicating that the
U6 promoter was active in BOSC23 cells. Next, we co-trans-
fected pCMS-eGFP with pBS/U6-Neo-eGFP (shown in Figure
1E) and found that this transfection yielded eGFP levels
comparable to those produced by the co-transfection of
pCMS-eGFP and pBS/U6 vector (Figure 2C). This observa-
tion indicated that the presence of the ploxPneo between DES
and PES disrupted the activity of the U6 promoter. Then, we
co-transfected pCMS-eGFP with pBS/U6-LoxP-eGFP vector
(shown in Figure 1F) and found that this vector could suffi-
ciently suppress eGFP expression (Figure 2D). This observa-
tion indicated that the presence of a loxP site did not have an
obvious effect on U6 promoter activity.
Next, we checked the efficiency of our system on the GFP
reporter after it was stably integrated into the genomic DNA.
We transfected a cell line, WO69, which was derived from a
Figure 2. Suppression of eGFP in BOSC23 and W069 cells. (A–D) Transient transfections of BOSC23 cells with pCMS-GFP and pBS/U6 (A), pBS/U6-eGFP (B),
pBS/U6-Neo-eGFP (C) and pBS/U6-LoxP-eGFP (D). Left, bright field control; right, green fluorescence. (E–H) W069 cells that are stably express eGFP are
transiently transfected with constructs indicated. Pictures are taken three days after transfections using lipofectamine 2000.
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mouse mammary tumor (17), with pCMS-eGFP, and enriched
GFP expressing cells by sorting them twice at 7 and 30 days
after transfection. We then transfected the eGFP-expressing
cells with the pBS/U6 (Figure 2E), pBS/U6-eGFP (Figure 2F),
pBS/U6-Neo-eGFP (Figure 2G) or pBS/U6-LoxP-eGFP (Fig-
ure 2H) vectors. We obtained similar results as shown in
transient system, i.e. the presence of the neo blocked the
U6 promoter activity and the removal of the neo restored
the promoter function. It is important to notice that we did
not modify the distance between each element of the promoter.
Even in an inserted LoxP site, we deleted on purpose the
corresponding number of base pairs that we add following
the insertion. As a result, we did not observe any differences
between the effects of the unmodified U6 and inserted LoxP-
U6 promoters. These data indicated that it is possible to use the
combination of RNAi and Cre–LoxP system to knock-down
the expression of genes that are stably integrated in the gen-
ome in an inducible manner.
Encouraged by these results, we tested the efficiency of
our system on an endogenous gene, Fgfr2, in mouse ES
cells. We chose to study this gene for several reasons.
First, FGFR2 is expressed in ES cells and we surmised
that down-regulation of this protein could have an effect
on the growth of those cells as demonstrated in other cell
types (22–25). Second, we have previously created a mouse
strain carrying Fgfr2 mutation through gene targeting
(23,26). The comparison between inducible Fgfr2 ‘knock-
down’ and Fgfr2 ‘knock-out’ mice would allow us to assess
efficiency of the RNAi system. Furthermore, mutant mice
bearing inducible suppression of Fgfr2 would be very useful
after crossing them with different Cre expressing mice to
assess functions of this gene in multiple biological processes
during mammalian development.
To this end, we constructed two plasmids carrying oligo-
nucleotides specific to different regions of Fgfr2 (pBS/
U6–Neo-Fgfr2). After testing the corresponding pBS/U6–
LoxP-Fgfr2 constructs (obtained through recombination in
Cre-positive bacteria) in transient transfections in mouse
embryonic fibroblasts, we found that one of the constructs
appeared to work better than the others (data not shown).
We then transfected it into an ES clone (referred to D4)
that we generated by stably expressing the recombinase
Cre-ERT2 (27,28). Seven days after transfection of the pBS/
U6-Neo-Fgfr2 into D4 ES cells, we picked 24 G418-resistant
colonies and amplified two of them (clones 1 and 75) for
further analysis. As both ES clones yielded similar results,
only the data obtained from clone 1 are presented below.
First, we performed RT-PCR of Fgfr2 following treatment
with vehicle or 4OH-tamoxifen (4HT) (1 mM) at varying time-
points from 24 to 96 h. A clear reduction of Fgfr2 is evident
24 h after 4HT treatment, with a dramatic effect after 96 h
compared to vehicle treatment (Figure 3A). To determine if
the decreased expression of Fgfr2 was a direct consequence of
Cre-mediated deletion of the pLoxPneo, we extracted the
genomic DNA from the ES cells and amplified by PCR a
specific region of pBS/U6-Neo-eGFP construct overlapping
both distal fragment of the U6 promoter and the 50 region
of the neomycine cassette. As shown in figure 3B, 24 h
after the 4HT treatment, Cre action, as evidenced by the
decreased intensities of PCR products, was already perceptible
and continued throughout the treatment until 72 h, while the
intensities of PCR products from vehicle treated cells
remained unchanged. This effect is observed even if the effi-
ciency of the recombination event does not reach 100%.
Indeed, this ‘mosaic’ effect is commonly observed in
mouse studies using the Cre–LoxP system. However, this
did not interfere with our following study.
Previous studies conducted in various types of cells indi-
cated that FGF/FGFR2 signals play an essential role in cell
proliferation (22–25). As our approach decreased Fgfr2 tran-
scripts by over 90% (Figure 3A), we were interested to
know whether the acute suppression of Fgfr2 could affect
ES cell proliferation. We performed a growth curve of clone
1 ES cells in the presence or absence of 4HT. As a control,
we used the parental D4 clone expressing only the Cre-ERT2
to ensure that an eventual effect could not be attributed to
action of the recombinase. Our data revealed no obvious
differences between 4HT treated, untreated and vehicle trea-
ted cells in both clone 1 and D4 cells between 24 and 96 h
(Figure 3C). However, a significant effect of 4HT on the
proliferation of clone 1 cells was observed at 120 h (30% of
decrease) (Figure 3C). Those effects are also observed with
the clone 75 (data not shown). The delayed response of cell
proliferation compared with decreased Fgfr2 transcripts may
suggest that the depletion of Fgfr2 protein to the critical
levels that impairs cell proliferation requires time. Alterna-
tively, the delay may happen somewhere in the Fgf/Fgfr2
signaling transduction pathway instead of at the receptor
level.
In addition, we have also assessed the impact of Fgfr2
suppression upon the treatment of 4HT on colony formation
in clone 1 cells in comparison with the parental D4 cells.
Figure 3D and E showed a significant decrease of the num-
ber and the size of colonies in 4HT-treated clones 1 and 75,
but not in vehicle-treated clone 1 cells. These effects were
consistent with the experiments on cell growth. In contrast,
such differences were not observed in D4 cells (Figure 3D
and E).
To confirm the viability of our system, we decided to per-
form the same experiments with another gene: Survivin, which
is a member of the inhibitor of apoptosis gene family. As
indicated by its name, Survivin inhibits apoptosis in vivo
and in vitro but is also implicated in cell division regulation
(29,30). We then designed an RNAi construct for Survivin
using the same approach for Fgfr2 and transfected it into
the parental ES clone D4. After neomycin selection of
more than 75 clones, clones 1 and 35 have been chosen to
perform the experiments according to their capacity to delete the
neo cassette following treatment by 1 mM of 4HT (Figure 4A).
Our time course RT–PCR revealed a sharp decrease of
Survivin mRNA levels after 24 h, a continuous ‘knock-
down’ effect even 120 h in the presence of 4HT (Figure 4B).
This observation correlates with decreased growth (almost
40% after 96 h) after several days of 4HT treatment com-
pared to vehicle (Figure 4C). Finally, we also performed a
colony formation experiment with both clones 1 and 35 and
yielded reduced sizes and numbers of colonies (Figure 4D
and E). The observed decreased growth is particularly cor-
related with the dramatic effect on colony sizes (Figure 4D).
These results confirmed that combination of the RNAi and
the Cre-LoxP system works efficiently in ES cells bearing the
shRNA conditional constructs.
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DISCUSSION
In summary, we have demonstrated the feasibility of a novel
technique that allows the inducible production of shRNA using
the U6 promoter and the Cre–LoxP system upon 4HT treat-
ment. At the cellular level, this system is applicable for estab-
lishing stable cell lines to decipher functions of genes, which
are essential for cell growth and viability. Indeed, even with an
uncompleted efficiency of recombination, we have observed
significant effects after down-regulation of Fgfr2 and Survivin.
Similarly, this system should be very useful in vivo for
functional analysis of genes in which the targeted disruption
is not compatible for embryonic or early postnatal develop-
ment. The techniques from ES cells to mouse germline trans-
mission have been well established (14,31); we believe that the
generation of mice via blastocyst injection of modified ES
cells, although time consuming, should not be a major con-
cern. To this end, successful germline transmission of ES cells
carrying non-inducible RNAi constructs have been achieved
recently (32). It has also been demonstrated that embryos
generated by tetraploid aggregation from ES cells carrying
an RNAi construct against Rasa1 recapitulated the null
Figure 3. Suppression of Fgfr2 in ES cells. (A) Kinetics of Fgfr2 levels revealed by RT–PCR after vehicle (V) or 4HT (T) treatment in Cre-ERT2 expressing ES cells
(Clone-1) that bear the pBS/U6-Neo-Fgfr2 construct. Gapdh is used as control. (B) Kinetics of removal of the neomycine cassette (Neo) evaluated by PCR on
genomic DNA isolated from ES cells after treatment by vehicle or 4HT (DNA control = Gapdh). (C) Growth curves of Cre-ERT2 expressing ES clones that bear
(Clone-1) or do not bear (parental D4) the pBS/U6-Neo-FGFR2 construct expressed by percentage ratio of the number cells after 4OH-Tamoxifen treatment (1 mM)
on the number of cells treated with ethanol (vehicle). (D and E) Colony formation of Clone D4 (parental), Clone-1 and Clone-75 ES (U6-Neo-FR2) cells. (D) The cells
are seeded one day before beginning of treatment by vehicle (ethanol) or 4HT. Pictures are taken 6 days later after staining by Accustain. (E) Relative values of colony
formation in D4 and Clone-1 ES cells. Number of colonies obtained from vehicle-treated are set as 100%, and those of 4HT-treated are calculated as following: nb. of
colonies from 4HT treatment/nb. of colonies from vehicle treatment·100/100. Six independent counts have been performed. Astral indicates significant difference as
assayed by Student’s t-test ( p < 0.01).
PAGE 5 OF 7 Nucleic Acids Research, 2004, Vol. 32, No. 10 e85
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/32/10/e85/1053647 by Inserm
/D
isc user on 04 July 2019
phenotype (33). Our method aims at generation of mice
carrying inducible RNAi constructs, which would allow the
utilization of large collection of Cre-transgenic mice to study
the consequence of decreased levels of gene expression in vivo
in animal models in a spatio–temporal dependant manner.
Recent investigations pointed out the fact that RNA inter-
ference could target other non-specific genes (34,35) while
others indicated that the repression by RNAi is highly specific
(36,37). Because the non-specific effect appears to be primar-
ily sequence-dependent, careful screening of RNAi sequences
is recommended to avoid potential problems. Furthermore,
majority of the studies used siRNA transiently transfected
at high levels, the observed non-specific response could be
due to the transient transfection of large amounts of siRNA. In
this case, we predict that a stable integrated vector strategy
combined with an inducible system could attenuate this
problem. Nonetheless, like all other newly developed technol-
ogies, RNAi system is not perfect at its current stand and needs
to be consistently improved in such a way that high specific
gene suppression at any given stages in vivo can be achieved.
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